Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare the Clinical and Radiological Efficacy of 625 mg Versus 1250 mg of Oral Methylprednisolone in Patients With Multiple Sclerosis in Relapse

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Relapsing-remitting MS (Mc Donald criteria 2010) regardless being under immunomodulatory treatment~2. EDSS (previous to relapse) between 0 and 5~3. MS relapse of moderate intensity (EDSS increase from 1 to 2.5 points) or severe intensity (EDSS increase \> 3 points)~   * If EDSS previous relapse is available:~     * optic neuritis, myelitis or brainstem relapse: the EDSS should increase of 1 point in visual, pyramidal or brainstem system function~    * relapse in other location or uncertain location: the EDSS should increase at least 1 point~  * If EDSS previous relapse is not available:~     * optic neuritis, myelitis or brainstem relapse: the visual, pyramidal or brainstem system function should be \> 2 points.~    * relapse in other location or uncertain location: EDSS should be \> 2 points~4. Recent clinical relapse onset (\<15 days) without fever~5. One month of clinical stability prior to relapse~6. Signed informed consent~7. Capacity to ingest the medication.~Exclusion Criteria:~1. Doubts about the diagnosis of multiple sclerosis~2. First episode of inflammatory neurological disease~3. Secondary progressive MS or primary progressive MS~4. Symptoms with lasted less than 24 hours of evolution~5. Any degree of subjective or objective remission~6. Treatment with corticosteroids during the previous 30 days~7. Patients with immunosuppressive treatment (azathioprine, mitoxantrone, cyclophosphamide) or Natalizumab or Fingolimod~8. Pregnancy or breastfeeding women or women of childbearing potential not using contraceptive measures~9. Diseases with a contraindication of treatment with corticosteroids~10. History of serious adverse reaction or hypersensitivity to drugs related to study medication~11. Patients who could not be regular MRI, not collaborators or who requires anesthesia.~12. Lactose intolerance~13. Patients with allergies to contrast used in MRI~14. Patients with renal impairment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- oMP 1250 mg: Group A (Type: ACTIVE_COMPARATOR): Methylprednisolone 1250 mg/24h x3 days
- oMP 625 mg: Group B (Type: ACTIVE_COMPARATOR): Methylprednisolone oral 625 mg/24h x3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).